Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ardelyx, Inc. - Common Stock (NQ:ARDX)

4.290 -0.070 (-1.61%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ardelyx, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
Recap: Ardelyx Q4 Earnings
 
Via Benzinga
Ardelyx Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
From Ardelyx, Inc.
Via GlobeNewswire
Analyst Upgrades: 3 Stocks Predicted to Soar In Q2 2024
Pounce on the electric surge of analyst upgrades, guiding you through market uncertainties with considerable aplomb. 
Via InvestorPlace
3 Revolutionary Biotech Stocks Poised for 10X Surge
Discover three biotech stocks set to soar in a $3.08 trillion market, merging medical innovations with financial growth opportunities. 
Via InvestorPlace
3 Unstoppable Russell 2000 to Buy in February
These are a few companies that are within the Russell 2000 Index that offer investors great returns and a bright future. 
Via InvestorPlace
How Is The Market Feeling About Ardelyx?
 
Via Benzinga
Wedbush Maintains Outperform Rating for Ardelyx: Here's What You Need To Know
 
Via Benzinga
Why Ardelyx Stock Is Climbing Higher
 
Via Benzinga
What Analysts Are Saying About Ardelyx Stock
 
Via Benzinga
3 Sleeper Stocks Under $15 Ready to Explode by 2029
Discover 3 under-$15 stocks primed for a 2029 explosion, from fintech disruptors to biotech pioneers tackling untreatable rare diseases. 
Via InvestorPlace
3 Strong Buy Biotech Stocks to Add to Your February Must-Watch List
These biotech stocks offer investors huge potential in the future. Investors may want to consider these equities to enter the industry. 
Via InvestorPlace
The 3 Best Biotech Stocks to Invest in for Big Gains in 2024
These pivotal biotech stocks for gains are charting the future of medicine and investment growth in 2024 offering powerful returns 
Via InvestorPlace
Ardelyx to Report Fourth Quarter and Full Year 2023 Financial Results on February 22, 2024
Conference call scheduled for 4:30 p.m. Eastern Time 
From Ardelyx, Inc.
Via GlobeNewswire
What's Going On With Ardelyx Stock?
Ardelyx, Inc. (NASDAQ: ARDX) shares are trading higher Monday after the company provided a strategic business update. 
Via Benzinga
The Latest Analyst Ratings for Ardelyx
 
Via Benzinga
3 Groundbreaking Biotech Stocks to Invest in Now
These are several biotech companies for investors seeking unique opportunities for great returns within the industry. 
Via InvestorPlace
7 Small-Cap Stocks to Buy for Big Gains in 2024
Small-cap stocks are a great way to diversify your portfolio and set yourself up for some potentially dynamic gains. 
Via InvestorPlace
3 mid-caps under $20 that Wall Street loves
MarketBeat's Stock Screener tool helped identify these three mid-cap stocks - with very bullish Wall Street sentiment - that are currently under $20 per share 
Via MarketBeat
Topics Artificial Intelligence Economy
Ardelyx, Inc. Reports Employment Inducement Grants
From Ardelyx, Inc.
Via GlobeNewswire
The 3 Best Under-$10 Stocks to Buy in January 2024
These are a few companies for investors looking for inexpensive options that still offer great earnings potential. 
Via InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
Nvidia, Boeing, Ardelyx, Crocs, Tesla: Why These 5 Stocks Are On Investors' Radars Today
 
Via Benzinga
Ardelyx Provides Update on Growing Commercial Momentum and 2024 Strategic Priorities
From Ardelyx, Inc.
Via GlobeNewswire
Why RxSight Shares Are Trading Higher By 20%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of RxSight, Inc. (NASDAQ: RXST) rose sharply during Monday’s session after the company issued preliminary FY23 and FY24 revenue guidance above estimates. Also, Needham maintained a Buy rating on... 
Via Benzinga
Ardelyx to Provide Company Update on IBSRELA® and Host a KOL Discussion on the IBS-C Landscape on Monday, January 8
Live event and webcast scheduled for 7:00 p.m. ET / 4:00 p.m. PT 
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx, Inc. Reports Employment Inducement Grants
From Ardelyx, Inc.
Via GlobeNewswire
Positive News For Skin Health: Aldeyra Therapeutics' ADX-629 Achieves Key Milestones in Atopic Dermatitis Study
Aldeyra Therapeutics Inc (NASDAQ: ALDX) released topline results from a Phase 2 clinical trial of ADX-629, an investigational RASP modulator, in  
Via Benzinga
Patient Demand Drives Ardelyx's Constipation Drug Success Amid IBS-C Treatment Gap, Says Analyst
Raymond James initiated coverage of Ardelyx Inc (NASDAQ: ARDX), noting the company's two early-stage launches underway for the same molecule with differentiated pricing: 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
3 Short-Squeeze Stocks Ready for a Year-End Rally
These are a few companies that have seen considerable gains this year that still have a large percentage of short interest. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.